glp 1 and glp 2 drugs MCT2D GLP-1 medications linked to major

Tirzepatide versus Semaglutide once Weekly in patients with type 2 diabetes

Stimulation by GLP-1RAs directly reduces CSF production through activation of cyclic adenosine monophosphate protein and subsequent phosphorylation of protein kinase A, which in turn inhibits sodium/potassium adenosine triphosphatase dependent secretion of CSF (11)

Sanofi Viking Therapeutics, Inc

The mechanistic foundation underlying this therapeutic versatility stems from the widespread distribution of the GLP-1 receptor and its pleiotropic signaling effects, which create a unified framework for understanding clinical benefits across seemingly disparate conditions

In 2024, the FDA approved Zepbound as the first GLP-1 medication specifically indicated to treat obstructive sleep apnea (OSA) in adults with obesity

doi: 10.1038/nchembio.209 [DOI] [PubMed] [Google Scholar] 78